Clinical trials: Inflammatory Bowel Disease 1
Crohns Disease
Protease Regulation and Impact of Sodium as Mechanisms of Inflammation in IBD
The study looks at how eating salt affects gut health in people with Crohn's disease. The aim of the study is to find out whether eating more salt increases the breakdown of proteins in the gut and if this makes inflammation and…
- Trial name
- PRISM-IBD (NCT07169123)
- Where
- 2 sites in Canada
- Volunteers
- 300 people
- Sponsor
- McMaster University
Crohn Disease
The Efficacy of Denosumab in Active Crohn's Disease
Denosumab, a fully human monoclonal antibody to RANKL was approved for the treatment of postmenopausal osteoporosis in June 2010.
- Trial name
- NCT02321280
- Testing
- Denosumab
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University of Manitoba
Crohn Disease
Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease
This protocol is designed to compare the effectiveness of two dietary interventions for patients with Crohn's disease (CD): the Specific Carbohydrate Diet (SCD) and a Mediterranean style diet (MSD) that has been demonstrated to…
- Trial name
- DINE-CD (NCT03058679)
- Testing
- Diet
- Where
- 35 sites in United States
- Volunteers
- 197 people
- Sponsor
- University of Pennsylvania
Crohn Disease
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
The purpose of this study is to examine the safety and efficacy of CNTO 1275 in participants with active Crohn's Disease.
- Trial name
- NCT00265122
- Testing
- Ustekinumab 90 mg, Ustekinumab 4.5 mg/kg
- Where
- 57 sites in United States, Belgium and 1 more
- Volunteers
- 131 people
- Sponsor
- Centocor, Inc.
Perianal Fistula, Crohn's Disease
Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)
A Phase II study to assess the safety and efficacy of AVB-114 in treatment of complex Crohn's perianal fistulas in subjects with quiescent rectal disease and whose fistula has failed to respond to biologic or conventional…
- Trial name
- NCT04847739
- Testing
- Seton Placement, AVB-114
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Avobis Bio, LLC
Crohn´s Disease
9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease
This study aims to evaluate the efficacy of 9 mg budesonide once daily (OD) versus 3 mg budesonide three-times daily (TID) for the induction of remission in Crohn's disease.
- Trial name
- NCT01086553
- Testing
- budesonide
- Where
- Germany
- Volunteers
- 471 people
- Sponsor
- Dr. Falk Pharma GmbH
Crohn's Disease
Drug-Disease Interaction in Crohn's Disease
Objective: To determine the effect of C-reactive protein (CRP) status, and infliximab treatment on the pharmacodynamics and pharmacokinetics of verapamil, a model drug for L-type calcium channel blocking, in Crohn's disease (CD)…
- Trial name
- NCT01261286
- Testing
- verapamil
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alberta
Ulcerative Colitis (UC), Crohn's Disease
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation…
- Trial name
- NCT04254783
- Testing
- Risankizumab, Cytochrome P450 (CYP) Substrates
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- AbbVie
Crohn's Disease
A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
The purpose of the study is to assess efficacy, safety and tolerability of 2 dose regimens of certolizumab pegol
- Trial name
- NCT04643483
- Testing
- Certolizumab pegol, Adalimumab
- Sponsor
- UCB Biopharma SRL
Nephrolithiasis, Hyperoxaluria
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
The purpose of this study was to determine the effect of two probiotic preparations (Agri-King Synbiotic and Oxadrop) on urinary oxalate excretion in patients with mild hyperoxaluria.
- Conditions
- Nephrolithiasis, Hyperoxaluria, Crohn's Disease
- Trial name
- NCT00587041
- Testing
- Oxadrop, Agri-King Synbiotic (AKSB)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Inflammatory Bowel Diseases, Ulcerative Colitis
Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease
Ulcerative colitis and Crohn's disease are the commonest types of inflammatory bowel disease (IBD). Both conditions range in severity from no symptoms to being potentially fatal.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT03836612
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 95,055 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Pediatric Crohns Disease
Clinical Hypnosis in Pediatric Crohn's Disease
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic, immune-mediated disease increasingly prevalent in youth.
- Trial name
- HypnoCrohns (NCT03809195)
- Testing
- Clinical Hypnosis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt University Medical Center
Crohn's Disease
Study to Determine Relationship Between Serum Infliximab and Efficacy in Luminal Crohn's Disease Patients
To assess the relationship between the change in Crohn's Disease Activity Index (CDAI) scores and trough serum infliximab concentration in subjects who are scheduled to receive infliximab infusions at an interval of 8 weeks.
- Trial name
- X-Sectional (NCT00676988)
- Where
- 2 sites in Canada
- Volunteers
- 327 people
- Sponsor
- University of Western Ontario, Canada
Crohn's Disease, Inflammatory Bowel Disease
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease, IBD, Colitis
- Trial name
- NCT01369342
- Testing
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Where
- 220 sites in United States, Australia and 20 more
- Volunteers
- 640 people
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Bowel Diseases, Children, Only
A Treat-to-target Strategy Using Pan-enteric Capsule Endoscopy (PCE) in Paediatric Crohn's Disease (CD).
This prospective, interventional study aims this to determine the efficacy and safety of a PCE-based treat-to-target strategy in order to achieve Mucosal Healing (MH) and deep remission (DR) of pediatric Crohn's Disease (CD) over…
- Trial name
- PCE (NCT03161886)
- Testing
- Pan-enteric Capsule Endoscopy (PCE)
- Volunteers
- 48 people
- Sponsor
- Azienda Policlinico Umberto I
Stenosis; Bowel, Crohn Disease
Clinical Trial to Evaluate if the Laparoscopic Administration of Cells Derived From the Fatty Tissue Can Improve the Inflammatory Stenosis in Patient With Crohn's Disease
A phase II, national, multicenter, uncontrolled and open trial to evaluate the feasibility and safety of laparoscopic administration of adipose derived allogenic mesenchymals stem cells (adMSC), for the treatment of patients with…
- Trial name
- MEIC (NCT05521672)
- Testing
- Adipose derived allogenic mesenchymal stem cells (adAMSC)
- Where
- 3 sites in Spain
- Volunteers
- 2 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Anastomotic Leak, Colorectal Cancer
The Prediction of Anastomotic Insufficiency Risk After Colorectal Surgery (PANIC) Study
The Prediction of Anastomotic Insufficiency risk after Colorectal surgery (PANIC) study aims to establish a machine-learning-based application that allows for accurate preoperative prediction of patients at risk for anastomotic…
- Conditions
- Anastomotic Leak, Colorectal Cancer, Diverticulosis, Crohn Disease
- Trial name
- NCT04985981
- Where
- 2 sites in Switzerland
- Volunteers
- 11,000 people
- Sponsor
- Michel Adamina, MD
Rheumatoid Arthritis, Spondyloarthritis
Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital
The purpose of this study is to evaluate the effectiveness of the switch from the original infliximab ( REMICADE®) to its biosimilar (INFLECTRA®) in all the patients at Cochin hospital receiving REMICADE® for either a rheumatic…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Crohn's Disease, Uveitis
- Trial name
- SIC (NCT02998398)
- Testing
- Switch from REMICADE® to INFLECTRA®
- Where
- France
- Volunteers
- 262 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Crohn's Disease
MICISPORT Survey : Questionnaire
This study offers a questionnaire to patients with Crohn's disease in order to assess their physical activity and / or sport as well as their eating habits in order to assess the impact of these lifestyle habits on activity and…
- Trial name
- MICISPORT (NCT04297566)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Crohn's Disease
Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat moderate to severe inflammatory, nonstricturing, nonpenetrating Crohn's disease.
- Trial name
- NCT00267722
- Testing
- Visilizumab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Facet Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.